NVAX – Novavax, Inc.
Novavax, Inc.NVAX
$6.39Name : Novavax, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,034,178,496.00
EPSttm : 2.75
Novavax, Inc.
$6.39
0.24%$0.015Float Short %
30.15
Margin Of Safety %
Put/Call OI Ratio
0.64
EPS Next Q Diff
-3.17
EPS Last/This Y
3.79
EPS This/Next Y
-2.24
Price
6.38
Target Price
13.43
Analyst Recom
2.71
Performance Q
-12.26
Relative Volume
0.43
Beta
2.73
Ticker: NVAX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | NVAX | 7.05 | 0.68 | 0.40 | 360666 |
| 2025-06-03 | NVAX | 7.26 | 0.68 | 0.13 | 367257 |
| 2025-06-04 | NVAX | 7.14 | 0.68 | 0.16 | 369488 |
| 2025-06-05 | NVAX | 6.99 | 0.68 | 0.32 | 374412 |
| 2025-06-06 | NVAX | 7.45 | 0.67 | 0.15 | 379489 |
| 2025-06-09 | NVAX | 7.41 | 0.67 | 0.24 | 364933 |
| 2025-06-10 | NVAX | 7.18 | 0.66 | 0.39 | 369504 |
| 2025-06-11 | NVAX | 7.09 | 0.66 | 0.49 | 372798 |
| 2025-06-12 | NVAX | 7.15 | 0.66 | 0.07 | 377225 |
| 2025-06-13 | NVAX | 6.93 | 0.66 | 0.38 | 379410 |
| 2025-06-16 | NVAX | 7.03 | 0.68 | 0.13 | 369294 |
| 2025-06-17 | NVAX | 6.53 | 0.67 | 0.12 | 372342 |
| 2025-06-18 | NVAX | 6.3 | 0.67 | 0.22 | 375423 |
| 2025-06-20 | NVAX | 6.41 | 0.66 | 0.37 | 379067 |
| 2025-06-23 | NVAX | 6.32 | 0.67 | 0.49 | 350475 |
| 2025-06-24 | NVAX | 6.49 | 0.66 | 0.11 | 352418 |
| 2025-06-25 | NVAX | 6.48 | 0.65 | 0.13 | 356277 |
| 2025-06-26 | NVAX | 6.51 | 0.65 | 0.54 | 358947 |
| 2025-06-27 | NVAX | 6.38 | 0.64 | 0.20 | 374454 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | NVAX | 7.07 | -124.2 | - | 2.56 |
| 2025-06-03 | NVAX | 7.26 | -124.2 | - | 2.56 |
| 2025-06-04 | NVAX | 7.14 | -124.2 | - | 2.56 |
| 2025-06-05 | NVAX | 6.99 | -124.2 | - | 2.56 |
| 2025-06-06 | NVAX | 7.44 | -124.2 | - | 2.56 |
| 2025-06-09 | NVAX | 7.41 | -124.2 | - | 2.56 |
| 2025-06-10 | NVAX | 7.20 | -124.2 | - | 2.56 |
| 2025-06-11 | NVAX | 7.09 | -124.2 | - | 2.56 |
| 2025-06-12 | NVAX | 7.15 | -124.2 | - | 2.56 |
| 2025-06-13 | NVAX | 6.93 | -124.2 | - | 2.56 |
| 2025-06-16 | NVAX | 7.03 | -124.2 | - | 2.56 |
| 2025-06-17 | NVAX | 6.49 | -124.2 | - | 2.56 |
| 2025-06-18 | NVAX | 6.30 | -124.2 | - | 2.56 |
| 2025-06-20 | NVAX | 6.41 | -120.2 | - | 2.56 |
| 2025-06-23 | NVAX | 6.33 | -120.2 | - | 2.56 |
| 2025-06-24 | NVAX | 6.49 | -120.2 | - | 2.56 |
| 2025-06-25 | NVAX | 6.48 | -120.2 | - | 2.56 |
| 2025-06-26 | NVAX | 6.50 | -120.2 | - | 2.56 |
| 2025-06-27 | NVAX | 6.38 | -120.2 | - | 2.56 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | NVAX | -0.10 | -4.87 | 31.48 |
| 2025-06-03 | NVAX | -0.10 | -4.87 | 31.48 |
| 2025-06-04 | NVAX | -0.10 | -4.87 | 31.48 |
| 2025-06-05 | NVAX | -0.10 | -4.87 | 31.48 |
| 2025-06-06 | NVAX | -0.10 | -4.87 | 31.48 |
| 2025-06-09 | NVAX | -0.10 | -4.87 | 31.48 |
| 2025-06-10 | NVAX | -0.10 | -4.87 | 31.48 |
| 2025-06-11 | NVAX | -0.10 | -4.87 | 30.28 |
| 2025-06-12 | NVAX | -0.10 | -4.87 | 30.28 |
| 2025-06-13 | NVAX | -0.10 | -4.87 | 30.28 |
| 2025-06-16 | NVAX | -0.10 | -4.88 | 30.28 |
| 2025-06-18 | NVAX | -0.10 | -4.88 | 30.28 |
| 2025-06-20 | NVAX | -0.10 | -4.88 | 30.29 |
| 2025-06-23 | NVAX | -0.10 | -4.89 | 30.30 |
| 2025-06-24 | NVAX | -0.10 | -4.89 | 30.30 |
| 2025-06-25 | NVAX | -0.10 | -4.89 | 30.30 |
| 2025-06-26 | NVAX | -0.10 | -4.89 | 30.15 |
| 2025-06-27 | NVAX | -0.10 | -4.89 | 30.15 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.93
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
-0.24
Insider Transactions
-0.1
Institutional Transactions
-4.89
Beta
2.73
Average Sales Estimate Current Quarter
147
Average Sales Estimate Next Quarter
100
Fair Value
Quality Score
96
Growth Score
35
Sentiment Score
23
Actual DrawDown %
98.1
Max Drawdown 5-Year %
-98.8
Target Price
13.43
P/E
2.4
Forward P/E
28.07
PEG
P/S
0.82
P/B
P/Free Cash Flow
EPS
2.65
Average EPS Est. Cur. Y
2.56
EPS Next Y. (Est.)
0.31
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
38.14
Relative Volume
0.43
Return on Equity vs Sector %
-656.7
Return on Equity vs Industry %
-638.9
EPS 1 7Days Diff
EPS 1 30Days Diff
0.16
EBIT Estimation
Novavax, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 952
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
stock quote shares NVAX – Novavax, Inc. Stock Price stock today
news today NVAX – Novavax, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NVAX – Novavax, Inc. yahoo finance google finance
stock history NVAX – Novavax, Inc. invest stock market
stock prices NVAX premarket after hours
ticker NVAX fair value insiders trading